TY - JOUR
T1 - Risk stratification in cardiomyopathy
AU - Sinagra, Gianfranco
AU - Carriere, Cosimo
AU - Clemenza, Francesco
AU - Minà, Chiara
AU - Bandera, Francesco
AU - Zaffalon, Denise
AU - Gugliandolo, Paola
AU - Merlo, Marco
AU - Guazzi, Marco
AU - Agostoni, Piergiuseppe
N1 - Funding Information:
This paper is dedicated to the memory of Professor Fulvio Camerini, foremost expert in cardiomyopathies, outstanding clinician and scientist. The author(s) would like to thank Fondazione CR Trieste, and FINCANTIERI for their support. They are also grateful to all the healthcare professionals for the continuous support to the research and clinical management of patients and families with cardiomyopathies followed in the HF outpatient clinic and cardiomyopathy centre of Trieste. The author(s) received no financial support for the research, authorship, and/or publication of this article.
Publisher Copyright:
© The European Society of Cardiology 2020.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Prognostic stratification of cardiomyopathies represents a cornerstone for the appropriate management of patients and is focused mainly on arrhythmic events and heart failure. Cardiopulmonary exercise testing provides additional prognostic information, particularly in the setting of heart failure. Cardiopulmonary exercise testing data, integrated in scores such as the Metabolism Exercise Cardiac Kidney Index score have been shown to improve the risk stratification of these patients. Cardiopulmonary exercise testing has been analysed as a potential supplier of prognostic parameters in the context of hypertrophic cardiomyopathy, for which it has been shown that a reduced oxygen consumption peak, an increased ventilation/carbon dioxide production slope and chronotropic incompetence correlate with a worse prognosis. To a lesser extent, in dilated cardiomyopathy, it has been shown that the percentage of oxygen consumption peak, not the pure value, and the ventilation/carbon dioxide production slope are associated with a greater cardiovascular risk. Few data are available about other cardiomyopathies (arrhythmogenic and restrictive). Cardiomyopathy patients should be early and routinely referred to heart failure advanced centres in order to perform a comprehensive risk stratification which should include a cardiopulmonary exercise test, with variables and cut-offs shown to improve their risk stratification.
AB - Prognostic stratification of cardiomyopathies represents a cornerstone for the appropriate management of patients and is focused mainly on arrhythmic events and heart failure. Cardiopulmonary exercise testing provides additional prognostic information, particularly in the setting of heart failure. Cardiopulmonary exercise testing data, integrated in scores such as the Metabolism Exercise Cardiac Kidney Index score have been shown to improve the risk stratification of these patients. Cardiopulmonary exercise testing has been analysed as a potential supplier of prognostic parameters in the context of hypertrophic cardiomyopathy, for which it has been shown that a reduced oxygen consumption peak, an increased ventilation/carbon dioxide production slope and chronotropic incompetence correlate with a worse prognosis. To a lesser extent, in dilated cardiomyopathy, it has been shown that the percentage of oxygen consumption peak, not the pure value, and the ventilation/carbon dioxide production slope are associated with a greater cardiovascular risk. Few data are available about other cardiomyopathies (arrhythmogenic and restrictive). Cardiomyopathy patients should be early and routinely referred to heart failure advanced centres in order to perform a comprehensive risk stratification which should include a cardiopulmonary exercise test, with variables and cut-offs shown to improve their risk stratification.
KW - Cardiomyopathy
KW - CPET
KW - exercise
KW - MECKY score
KW - prognosis
KW - risk stratification
UR - http://www.scopus.com/inward/record.url?scp=85096744263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096744263&partnerID=8YFLogxK
U2 - 10.1177/2047487320961898
DO - 10.1177/2047487320961898
M3 - Article
C2 - 33238741
AN - SCOPUS:85096744263
SN - 2047-4873
VL - 27
SP - 52
EP - 58
JO - European Journal of Preventive Cardiology
JF - European Journal of Preventive Cardiology
IS - 2_suppl
ER -